Athira Pharma (NASDAQ:ATHA) & InflaRx (NASDAQ:IFRX) Financial Survey

Athira Pharma (NASDAQ:ATHA) and InflaRx (NASDAQ:IFRX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, institutional ownership, profitability, dividends and earnings.

Volatility and Risk

Athira Pharma has a beta of 2.79, meaning that its stock price is 179% more volatile than the S&P 500. Comparatively, InflaRx has a beta of 1.48, meaning that its stock price is 48% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Athira Pharma and InflaRx, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Athira Pharma	1	0	0	0	1.00
InflaRx	1	1	5	0	2.57

Athira Pharma presently has a consensus price target of $4.00, suggesting a potential downside of 57.31%. InflaRx has a consensus price target of $6.17, suggesting a potential upside of 504.58%. Given InflaRx’s stronger consensus rating and higher possible upside, analysts plainly believe InflaRx is more favorable than Athira Pharma.

Earnings & Valuation

This table compares Athira Pharma and InflaRx”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athira Pharma	N/A	N/A	-$96.94 million	($9.68)	-0.97
InflaRx	$62,839.00	1,099.67	-$51.63 million	($0.76)	-1.34

InflaRx has higher revenue and earnings than Athira Pharma. InflaRx is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

57.1% of Athira Pharma shares are held by institutional investors. Comparatively, 42.4% of InflaRx shares are held by institutional investors. 19.8% of Athira Pharma shares are held by insiders. Comparatively, 16.3% of InflaRx shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Athira Pharma and InflaRx’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Athira Pharma	N/A	-107.06%	-89.89%
InflaRx	N/A	-80.51%	-61.36%

Summary

InflaRx beats Athira Pharma on 8 of the 12 factors compared between the two stocks.

About Athira Pharma

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.

About InflaRx

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.